Signaturefd, LLC Cure Vac N.V. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Signaturefd, LLC holds 27,970 shares of CVAC stock, worth $77,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,970

Previous 22,043 26.89%

Holding current value

$77,476

Previous $74,000 10.81%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$2.74 - $3.79 $16,239 - $22,463	5,927 Added 26.89%	27,970 $82,000
Q2 2024 Jul 29, 2024	BUY	$2.31 - $4.99 $35,580 - $76,860	15,403 Added 231.97%	22,043 $74,000
Q1 2024 May 03, 2024	BUY	$2.94 - $4.34 $13,588 - $20,059	4,622 Added 229.04%	6,640 $20,000
Q4 2023 Jan 31, 2024	SELL	$3.96 - $6.41 $12,006 - $19,435	-3,032 Reduced 60.04%	2,018 $8,000
Q3 2023 Nov 03, 2023	SELL	$6.5 - $10.77 $1,872 - $3,101	-288 Reduced 5.4%	5,050 $34,000
Q2 2023 Aug 01, 2023	BUY	$6.69 - $12.25 $29,328 - $53,704	4,384 Added 459.54%	5,338 $55,000
Q1 2023 Apr 28, 2023	SELL	$6.38 - $12.5 $1,601 - $3,137	-251 Reduced 20.83%	954 $6,000
Q4 2022 Jan 27, 2023	BUY	$5.75 - $8.5 $2,955 - $4,369	514 Added 74.38%	1,205 $7,000
Q3 2022 Nov 08, 2022	BUY	$7.48 - $15.24 $351 - $716	47 Added 7.3%	691 $5,000
Q2 2022 Aug 10, 2022	SELL	$13.18 - $19.41 $23,038 - $33,928	-1,748 Reduced 73.08%	644 $9,000
Q1 2022 May 02, 2022	BUY	$14.73 - $35.25 $24,437 - $58,479	1,659 Added 226.33%	2,392 $47,000
Q4 2021 Jan 25, 2022	BUY	$33.72 - $48.22 $23,671 - $33,850	702 Added 2264.52%	733 $25,000
Q3 2021 Oct 28, 2021	BUY	$49.26 - $74.5 $1,527 - $2,309	31 New	31 $2,000

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $519M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account